| OMEROS CORP. DL -,01 |
| USA |
| Gesundheit |
| US6821431029 / A0NBFF |
| 3O8 (Frankfurt) / OMER (NASDAQ) |
| FRA:3O8, ETR:3O8, 3O8:GR, NASDAQ:OMER |
| - |
| https://www.omeros.com/ |
|
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected ..
>Volltext.. |
| 1225.2 Mio. EUR |
| 1370.17 Mio. EUR |
| 34.44 Mio. EUR |
| -64.46 Mio. EUR |
| 111.9 Mio. EUR |
| 1.54 EUR |
| 266.14 Mio. EUR |
| 1.78 Mio. EUR |
| -67.28 Mio. EUR |
| 1.39 |
| - |
| - |
| - |
| - |
| - |
| OMEROS |
| 16.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|